These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 10388221)

  • 1. Drug price divergence in Europe: regulatory aspects.
    Huttin C
    Health Aff (Millwood); 1999; 18(3):245-9. PubMed ID: 10388221
    [No Abstract]   [Full Text] [Related]  

  • 2. Addressing Pharmaceutical Price Spikes Through Generic Preclearance.
    Sachs RE
    J Leg Med; 2019; 39(2):169-176. PubMed ID: 31503530
    [No Abstract]   [Full Text] [Related]  

  • 3. A comparative study of European rare disease and orphan drug markets.
    Denis A; Mergaert L; Fostier C; Cleemput I; Simoens S
    Health Policy; 2010 Oct; 97(2-3):173-9. PubMed ID: 20800761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. European healthcare policies for controlling drug expenditure.
    Ess SM; Schneeweiss S; Szucs TD
    Pharmacoeconomics; 2003; 21(2):89-103. PubMed ID: 12515571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Case Study of Pharmaceutical Pricing in China: Setting the Price for Off-Patent Originators.
    Hu S; Zhang Y; He J; Du L; Xu M; Xie C; Peng Y; Wang L
    Appl Health Econ Health Policy; 2015 Aug; 13 Suppl 1(Suppl 1):S13-20. PubMed ID: 26091710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pricing and reimbursement of pharmaceuticals in the Czech Republic and Sweden.
    Davidova J; Praznovcova L; Lundborg CS
    Pharm World Sci; 2008 Jan; 30(1):57-64. PubMed ID: 17588212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prescription-drug prices.
    Frank RG
    N Engl J Med; 2004 Sep; 351(14):1375-7. PubMed ID: 15459294
    [No Abstract]   [Full Text] [Related]  

  • 8. Generic drugs: international trends and policy developments in Australia.
    Lofgren H
    Aust Health Rev; 2004; 27(1):39-48. PubMed ID: 15362295
    [TBL] [Abstract][Full Text] [Related]  

  • 9. States on the Front Line: Addressing America's Drug Pricing Problem.
    Riley T; Lanford S
    J Leg Med; 2019; 39(2):81-93. PubMed ID: 31503529
    [No Abstract]   [Full Text] [Related]  

  • 10. Pharmaceutical policy in Italy: towards a structural change?
    Ghislandi S; Krulichova I; Garattini L
    Health Policy; 2005 Apr; 72(1):53-63. PubMed ID: 15760698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmaceutical pricing, price controls, and their effects on pharmaceutical sales and research and development expenditures in the European Union.
    Vogel RJ
    Clin Ther; 2004 Aug; 26(8):1327-40; discussion 1326. PubMed ID: 15476914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pricing and reimbursement of pharmaceuticals in Sweden.
    Jönsson B
    Pharmacoeconomics; 1994; 6 Suppl 1():51-60. PubMed ID: 10172482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Do pharmaceutical prices respond to potential patient out-of-pocket expenses?
    Pavenik N
    Rand J Econ; 2002; 33(3):469-87. PubMed ID: 12585303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmaceuticals and Medical Devices: Cost Savings.
    Steiner DJ;
    Issue Brief Health Policy Track Serv; 2016 Dec; 2016():1-31. PubMed ID: 28252884
    [No Abstract]   [Full Text] [Related]  

  • 15. [Generic medicines].
    Peláez de Loño J
    Rev Enferm; 1999 Dec; 22(12):836-43. PubMed ID: 10797771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmaceuticals and Medical Devices: Medicare Part D.
    Steiner DJ;
    Issue Brief Health Policy Track Serv; 2016 Dec; 2016():1-31. PubMed ID: 28252885
    [No Abstract]   [Full Text] [Related]  

  • 17. Expansion of the Medicare 340B Payment Program: Hospital Participation, Prescribing Patterns and Reimbursement, and Legal Challenges.
    Bach PB; Sachs RE
    JAMA; 2018 Dec; 320(22):2311-2312. PubMed ID: 30453324
    [No Abstract]   [Full Text] [Related]  

  • 18. The state and consequences of dermatology drug prices in the United States.
    Albrecht J; Lebwohl M; Asgari MM; Bennett DD; Cook A; Evans CC; Green LJ; Hodge JA; Kourosh AS; Maloney ME; Howard LM; Olsen EA; Rosenberg SP; Rubin A; Stough DB; Taylor SC; Brod BA
    J Am Acad Dermatol; 2016 Sep; 75(3):603-605. PubMed ID: 27423978
    [No Abstract]   [Full Text] [Related]  

  • 19. Drug pricing: the end of the gravy train?
    Bateman C
    S Afr Med J; 2003 Nov; 93(11):812-3. PubMed ID: 14677496
    [No Abstract]   [Full Text] [Related]  

  • 20. Prescription-drug coupons--no such thing as a free lunch.
    Ross JS; Kesselheim AS
    N Engl J Med; 2013 Sep; 369(13):1188-9. PubMed ID: 23984672
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.